Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions | British Journal of Cancer
Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors | Bentham Science
Cancers | Free Full-Text | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Poly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancers
Cancers | Free Full-Text | PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Frontiers | Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
JCI - The evolving landscape of predictive biomarkers of response to PARP inhibitors
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
PARP inhibitors stumble in breast cancer | Nature Biotechnology
Epigenetic marker contributes to PARP inhibitor resistance | Center for Cancer Research
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy - Yusoh - 2020 - ChemMedChem - Wiley Online Library
Mechanisms of resistance to PARP inhibitors. Cancer cells develop... | Download Scientific Diagram
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
PARP Inhibitors: Where Are We in 2020 and What's Coming Next?
PARP inhibitors mechanisms of action and resistance. The left part of... | Download Scientific Diagram
Unsprung traps keep PARP inhibitors effective | Nature Cell Biology
Frontiers | The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Mode of Action | OncologyPRO
JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
PARP inhibitors: Synthetic lethality in the clinic | Science
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
Role of PARP Inhibitors in BRCA-Related Malignancies
